4D Molecular Therapeutics (FDMT)
(Delayed Data from NSDQ)
$23.96 USD
-0.94 (-3.78%)
Updated May 29, 2024 04:00 PM ET
After-Market: $23.96 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
FDMT 23.96 -0.94(-3.78%)
Will FDMT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for FDMT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FDMT
4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates
FDMT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?
All You Need to Know About 4D Molecular Therapeutics, Inc. (FDMT) Rating Upgrade to Strong Buy
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates
Other News for FDMT
Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Dynavax (DVAX) and Natera (NTRA)
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), AMN Healthcare Services (AMN) and 4D Molecular Therapeutics (FDMT)
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), 4D Molecular Therapeutics (FDMT) and Sanofi (OtherSNYNF)
Analysts Are Bullish on Top Healthcare Stocks: Processa Pharmaceuticals (PCSA), Oculis Holding (OCS)
4D Molecular Therapeutics Inc (FDMT) Q1 2024 Earnings: Misses Analyst Net Income Projections